The Post Office has announced plans to sell off its remaining directly-owned branches, putting around 1,000 employees at risk ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Key points A 47-year-old French-speaking woman of African descent presented to the emergency department with a 1-week history of severe foot pain and difficulty walking. For the preceding 2 months she ...

Team IMPACT, an non-profit group that joins colleges with children who have serious illnesses and disabilities, paired 12 ...

Individuals who live in areas with a higher social vulnerability index (SVI) have an increased risk for incident Alzheimer disease (AD) and a faster rate of cognitive decline.

Similar to many of my colleagues in medicine, I see firsthand how vitally important access to affordable medication is for ...

Researchers at Yale Cancer Center have made a breakthrough finding that could lead to a therapies for glioblastoma and other aggressive cancers that are extremely difficult to treat. Dr. James Hansen, ...

Join our loyalty program to support our work and go ad-free. You've supported HuffPost before, and we'll be honest — we could use your help again. We won't back down from our mission of providing free ...

Charles River Laboratories International, Inc. and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other ...

The Google Mobile Ads SDK is the latest generation in Google mobile advertising featuring refined ad formats and streamlined APIs for access to mobile ad networks and advertising solutions. The SDK ...

“The study showed that when we removed this content, there was no change to Search ad revenue and a <1% (0.8%) drop in usage,” Google said. Paul Liu, Google's director of economics, said in ...

the start of Phase 2 trial of A-005 in multiple sclerosis in the second half of 2025, and expect data from ESK-001’s Phase 2b clinical trial in systemic lupus erythematosus in 2026.